University of Hawaii;GalPharma Co., Ltd.;Blood Systems, Inc.
发明人:
Satish K. Pillai,Mohamed Abdel-Mohsen,Leonard Chavez,Lishomwa Ndhlovu,Ravi Tandon,Toshiro Niki,Misuomi Harashima
申请号：
US15558178
公开号：
US20180153901A1
申请日:
2016.03.10
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The present invention relates to the seminal discovery of methods of using recombinant galectin proteins to reverse HIV latency. Specifically, the present invention relates to the use of recombinant galectin-9 (rGal-9) to reactivate latent HIV, wherein the HIV is hypermutated rendering the virus replication incompetent. Further, rGal-9 induces the expression of APOBEC3 cytidine deaminases and NFkB pathway components and decreases histone deacetylase (HDAC) expression.
